Short answer
Greenwich LifeSciences, Inc. (GLSI) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$4M
- +1.9% YoY · +30.2% QoQ
- EPS (diluted)
- −$0.26
- +13.3% YoY · +33.3% QoQ
Source: XBRL data from the Greenwich LifeSciences, Inc. (GLSI) Q2 2026 10-Q on SEC EDGAR. USD.
Greenwich LifeSciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; clinical-stage company with no commercialization
- R&D expense $3.56M, up 4% from $3.42M; clinical expenses primary driver
- G&A expense $463K, up 31% from $353K; employee, management, and board options grant
- Cash $8.88M vs $6.18M at December 31, 2025; operating cash use $6.64M vs $4.07M
- ATM financing net proceeds $9.34M; additional capital required for operations and clinical trials
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Greenwich LifeSciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.